FDA Label for Fludeoxyglucose F18
View Indications, Usage & Precautions
Fludeoxyglucose F18 Product Label
The following document was submitted to the FDA by the labeler of this product The University Of Texas Md Anderson Cancer Center. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.
3 Dosage Forms And Strengths
Multiple-dose vial containing:
- 0.74 - 11.1 GBq/mL (20 - 300 mCi/mL) of Fludeoxyglucose F18 Injection and a 4.5 mg of sodium chloride in citrate buffer (approximately 27 mL volume), for intravenous administration
- 0.74 - 5.55 GBq/mL (20 - 150 mCi/mL) of Fludeoxyglucose F18 Injection and a 4.5 mg of sodium chloride in phosphate buffer (approximately 15 mL volume), for intravenous administration
or
6 Adverse Reactions
Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available.
Other
Manufactured and Distributed by:
The University of Texas MD Anderson Cancer Center
Cyclotron Radiochemistry Facility
1881 East Road
Houston, TX 77054
Final Product Labels
FDG Citrate Formulation
16 How Supplied/Storage And Handling
Fludeoxyglucose F 18 Injection is supplied in a multi-dose, 30 mL glass vial containing:
- between 0.740 - 11.1 GBq/mL (20 - 300 mCi/mL), of no carrier added 2-deoxy-2-[F 18] fluoro-D-glucose, at end of synthesis, in approximately 27 mL. Citrate Buffer Formulation: NDC 60215-411-30
- between 0.740 - 5.55 GBq/mL (20 - 150 mCi/mL), of no carrier added 2-deoxy-2-[F 18] fluoro-D-glucose, at end of synthesis, in approximately 15 mL. Phosphate Buffer Formulation: NDC 60215-411-15
or
The total volume and total radioactivity per vial are variable. The contents of each vial are sterile, pyrogen-free and preservative free. Each vial is enclosed in a shielding container of appropriate thickness.
Storage
Store the Fludeoxyglucose F 18 Injection vial upright in a shielded container at 10 - 25°C (68 - 77°F), excursions permitted to 15 - 30°C (59 - 86°F) [See USP Controlled Room Temperature].
Handling
Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.
11.0 Description
11.1 Chemical Characteristics
Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient 2-deoxy-2-[18F]fluoro-D-glucose has the molecular formula of C6H1118FO5 with a molecular weight of 181.26, and has the following chemical structure:
11.2 Physical Characteristics
Fluorine F 18 has a physical half-life of 109.7 minutes and decays to Oxygen O 18 (stable) by positron decay. The principal photons useful for imaging are the dual 511 keV “annihilation” gamma photons that are produced and emitted simultaneously in opposite directions when the positron interacts with an electron (Table 2).
* Please review the disclaimer below.